within Pharmacolibrary.Drugs.ATC.C;

model C05BX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 3.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.010199999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Calcium dobesilate is a synthetic vascular protective agent primarily used in the treatment of chronic venous insufficiency and diabetic retinopathy. It acts by reducing capillary permeability and improving microcirculation. The drug is approved and utilized in several countries, especially in Europe, but it is not approved in the United States.</p><h4>Pharmacokinetics</h4><p>Single-dose pharmacokinetic profile in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Wang, Y, et al., &amp; Wang, F (2024). Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Oral Formulations of Calcium Dobesilate Capsules in Healthy Chinese Volunteers Under Fasting and Fed Conditions. <i>Clinical pharmacology in drug development</i> 13(4) 360–366. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1376&quot;>10.1002/cpdd.1376</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38226890/&quot;>https://pubmed.ncbi.nlm.nih.gov/38226890</a></p></li><li><p>Leite, EB, et al., &amp; Cunha-Vaz, JG (1990). Effect of calcium dobesilate on the blood-retinal barrier in early diabetic retinopathy. <i>International ophthalmology</i> 14(2) 81–88. DOI:<a href=&quot;https://doi.org/10.1007/BF00154206&quot;>10.1007/BF00154206</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2187006/&quot;>https://pubmed.ncbi.nlm.nih.gov/2187006</a></p></li><li><p>Angulo, J, et al., &amp; Sáenz de Tejada, I (2003). Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries. <i>British journal of pharmacology</i> 139(4) 854–862. DOI:<a href=&quot;https://doi.org/10.1038/sj.bjp.0705293&quot;>10.1038/sj.bjp.0705293</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12813009/&quot;>https://pubmed.ncbi.nlm.nih.gov/12813009</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C05BX01;
